Clinical Trial: The Clinical Trial of Tamibarotene for Patients With HFpEF (RELIEF Trial)

U.S., Oct. 3 -- ClinicalTrials.gov registry received information related to the study (NCT07855692) titled 'The Clinical Trial of Tamibarotene for Patients With HFpEF (RELIEF Trial)' on Sept. 28.

Brief Summary: This study will evaluate the effect of 12 weeks of treatment with tamibarotene compared with placebo on N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels in patients with heart failure with preserved ejection fraction (HFpEF).

Study Start Date: Oct. 01

Study Type: INTERVENTIONAL

Condition: HFpEF - Heart Failure With Preserved Ejection Fraction

Intervention: DRUG: Tamibarotene

Tamibarotene 4 mg is administered orally once daily after breakfast for 12 weeks.

DRUG: Placebo

Placebo is administered orally once daily a...